Identification of Annexin A1 protein expression in human gastric adenocarcinoma using proteomics and tissue microarray

Table 3 Relationship between annexin A1 protein expression and clinicopathological parameters of gastric carcinoma n (%)

Parametes	n	ANXA1 cases				Wilcoxon	P value
		-	+	+ +	+ + +
Sex						1039.5	0.290
Male	50	15 (30.0)	7 (14.0)	17 (34.0)	11 (22.0)
Female	25	8 (32.0)	4 (16.0)	9 (36.0)	4 (16.0)
Age (yr)						840.0	0.394
≤ 60	24	7 (29.2)	5 (20.8)	10 (41.7)	2 (8.3)
> 60	51	16 (31.4)	6 (11.7)	16 (31.4)	13 (25.5)
Histological differentiation						1350.0	0.520
High	34	10 (29.4)	4 (11.8)	12 (35.3)	8 (23.5)
Moderate/poor	41	13 (31.7)	7 (17.1)	14 (34.1)	7 (17.1)
Invasive depth						514.5	0.008
T1-2	19	10 (52.6)	4 (21.1)	3 (15.8)	2 (10.5)
T3-4	56	13 (23.2)	7 (12.5)	23 (41.1)	13 (23.2)
N stage						929.0	0.017
N0	30	12 (40.0)	6 (20.0)	10 (33.3)	2 (6.7)
N1-3	45	11 (24.4)	5 (11.1)	16 (35.6)	13 (28.9)
M stage						348.5	0.017
M0	69	23 (33.3)	10 (14.5)	25 (36.2)	11 (15.9)
M1	6	0 (0)	1 (16.7)	1 (16.7)	4 (66.7)
TNM stage						1014.5	0.000
I-II	37	20 (54.1)	4 (10.8)	11 (29.7)	2 (5.4)
III-IV	38	3 (2.6)	7 (10.5)	15 (42.1)	13 (44.7)
Tumor size						1403.0	0.9735
≤ 5 cm	38	11 (28.9)	6 (15.8)	14 (36.8)	7 (18.4)
< 5 cm	37	12 (32.4)	5 (13.5)	12 (32.4)	8 (21.6)

ANXA1: Annexin A1; TNM: Tumour-lymph node metastasis.